Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age.

Trial Profile

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 02 Dec 2010 Additional location Canada identified as reported by ClinicalTrials.gov.
    • 02 Dec 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 02 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top